SynthesisNeurology2017
Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations.
Abstract readSystematic Review
In one paragraph
Synthesis in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.The oncologist · 2020Trial
- Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Trial
- Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026Review
- Outcome Measures to Assess the Effectiveness of Exercise Interventions on Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Scoping Review.Current oncology (Toronto, Ont.) · 2026Article
- Describing the minimally clinically important difference of a chemotherapy-induced peripheral neuropathy patient-reported outcome measure in young adults.Asia-Pacific journal of oncology nursing · 2025Article
- Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial.Frontiers in oncology · 2025Article
- Repurposing chemotherapy-induced peripheral neuropathy grading.European journal of neurology · 2024Article
- Exploring the reliability and validity of clinically-relevant outcome measures for chemotherapy-induced peripheral neuropathy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Summary of evidence on comprehensive healthcare for chemotherapy-induced peripheral neuropathy in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Review
- Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy.Cancers · 2023Article
- Crosstalk of Mast Cells and Natural Killer Cells with Neurons in Chemotherapy-Induced Peripheral Neuropathy.International journal of molecular sciences · 2023Review
- Personalized Medicine in Cancer Pain Management.Journal of personalized medicine · 2023Review
- The Role of Selenium and Manganese in the Formation, Diagnosis and Treatment of Cervical, Endometrial and Ovarian Cancer.International journal of molecular sciences · 2023Review
- Review
- Identifying participants' preferences for modifiable chemotherapy-induced peripheral neuropathy prevention clinical trial factors: an adaptive choice-based conjoint analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Pharmacological and Nonpharmacological Management of Chemotherapy-Induced Peripheral Neuropathy: A Scoping Review of Randomized Controlled Trials.Journal of palliative medicine · 2022Article
- Review
- Review
- Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment.Oncology and therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Jennifer S GewandterFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle. jennifer_gewandter@urmc.rochester.edu.
Roy FreemanFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
Rachel A KittFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
Guido CavalettiFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
Lynn R GauthierFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
Michael P McDermottFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
Nimish A MohileFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
Supriya G MohlieFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
A Gordon SmithFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
Mohamedtaki A TejaniFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
Dennis C TurkFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
Robert H DworkinFrom the Departments of Anesthesiology (J.S.G., R.A.K., R.H.D.), Biostatistics and Computational Biology (M.P.M.), Neurology (N.A.M., M.A.T.), and Medicine, Hematology/Oncology (S.G.M.), University of Rochester, NY; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Experimental Neurology Unit (G.C.), School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Family Medicine and Emergency Medicine (L.R.G.), Faculty of Medicine, Université Laval, Québec, Canada; Department of Neurology (A.G.S.), University of Utah, Salt Lake City; and Department of Anesthesiology and Pain Medicine (D.C.T.), University of Washington, Seattle.
Funding
URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7MCancer Control Research Training Curriculum (R25T)R25CA102618 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C, MORROW, GARY R · 2004 to 2018
$6.7MFDA HHS U01 FD005936NCI NIH HHS R25 CA102618NCI NIH HHS UG1 CA189961
Abstract
objectiveTo assess the design characteristics and reporting quality of published randomized controlled trials (RCTs) for treatments of chemotherapy-induced peripheral neuropathy (CIPN) initiated before or during chemotherapy.
methodsIn this systematic review of RCTs of preventive or symptomatic pharmacologic treatments for CIPN initiated before or during chemotherapy treatment, articles were identified by updating the PubMed search utilized in the CIPN treatment guidelines published in the
resultsThirty-eight articles were identified. The majority included only patients receiving platinum therapies (61%) and used a placebo control (79%). Common exclusion criteria were preexisting neuropathy (84%), diabetes (55%), and receiving treatments that could potentially improve neuropathy symptoms (45%). Ninety-five percent of studies initiated the experimental treatment before CIPN symptoms occurred. Although 58% of articles identified a primary outcome measure (POM), only 32% specified a primary analysis. Approximately half (54%) of the POMs were patient-reported outcome measures of symptoms and functional impairment. Other POMs included composite measures of symptoms and clinician-rated signs (23%) and vibration tests (14%). Only 32% of articles indicated how data from participants who prematurely discontinued chemotherapy were analyzed, and 21% and 29% reported the number of participants who discontinued chemotherapy due to neuropathy or other/unspecified reasons, respectively.
conclusionsThese data identify reporting practices that could be improved in order to enhance readers' ability to critically evaluate RCTs of CIPN treatments and use the findings to inform the design of future studies and clinical practice. Reporting recommendations are provided.
Indexed as
Antineoplastic AgentsHumansPeripheral Nervous System DiseasesRandomized Controlled Trials as TopicAntineoplastic Agents
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.